Urea Breath Tests - general information
Helicobacter pylori is a gram negative microaerophilic curved bacillus with an affinity for human gastric mucosa.
The organism is prevalent in up to 54% of the population in developed countries such as Australia. Acquisition occurs with age at a rate of 0.5-1% per year. Studies have shown it to be present in up to 100% of patients with duodenal and gastric ulceration, up to 94% of patients with gastric cancer, 92% with gastric lymphoma and 92% of patients with active chronic gastritis. It has been associated with non-ulcer dyspepsia.
Eradication of the organism leads to the disappearance of gastritis and has been shown to significantly reduce the relapse rate of duodenal ulcer disease. The one year relapse rate for duodenal ulcer treated with conventional acid suppression, is as high as 80% but can be reduced to almost zero with successful eradication of the organism, thus modifying the natural history of the disease.
Regression of low grade gastric MALT lymphoma has been shown with H. pylori eradication. In gastric carcinoma, epidemiological studies have identified a link between the organism and the development of cancer. The organism has been shown in some studies to increase gastric epithelial cell proliferation which may then be associated with an increased risk of carcinoma but the details of the exact pathogenic mechanism are unclear.
Diagnostic tests for H. pylori
Can be performed on biopsies obtained at upper Gastro
Intestinal endoscopy, and are evaluated by :
Non-invasive tests include :
Principles of Urea Breath Testing
Subjects are given urea labelled with 14C or 13C orally.
Indications for Urea Breath Testing
A Medicare benefit (item 12533) is payable if the patient is referred by another medical practitioner.
Sitemap | © 1997-2009, Nuclear Medicine, PET & Bone Densitometry, Royal Adelaide Hospital | Last major modification : February 2009 | Disclaimer | Link to us
|